Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 26 - 29 October 2026

European Medicines Agency Version 1 original current

Imported from official source

PRAC starts review of depression and anxiety medicine Deanxit (flupentixol/melitracen)PRAC has started a review of Deanxit, a fixed-dose combination medicine for treating…, Agenda Agenda of the PRAC meeting 26 - 29 October 2026Draft Reference Number: EMA/PRAC/227255/2026…, PRAC statistics: November 2026 Monthly figures for PRAC outcomes based on the draft agenda. , PRAC statistics:…, Ongoing referrals Procedure: Flupentixol/melitracen-containing medicinal products - referralProcedure: Parenteral iron-containing medicinal products - referral, Glossary Safety signal assessments. A safety signal is information which suggests a new potentially causal association, or a new aspect of a known association between…

This version

Version
1 of 1
Recorded
October 30, 2026 12:00
Change
Initial
Content hash
e1b26a5629dff99710f11a68b4b8e4d1
All versions
Revision history

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.